| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2019 | 849 | 1.160 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2025 | 187 | 0.970 |
Why?
|
| Methotrexate | 2 | 2025 | 342 | 0.890 |
Why?
|
| Hemangioendothelioma | 2 | 2022 | 25 | 0.780 |
Why?
|
| Drug Monitoring | 1 | 2025 | 285 | 0.730 |
Why?
|
| Vascular Malformations | 2 | 2022 | 109 | 0.710 |
Why?
|
| Medical Oncology | 4 | 2018 | 237 | 0.500 |
Why?
|
| Hyperglycemia | 2 | 2009 | 234 | 0.500 |
Why?
|
| Patient Rights | 1 | 2014 | 49 | 0.410 |
Why?
|
| Treatment Refusal | 1 | 2014 | 78 | 0.400 |
Why?
|
| Hodgkin Disease | 3 | 2012 | 312 | 0.380 |
Why?
|
| Hospitals | 1 | 2015 | 445 | 0.370 |
Why?
|
| Patient Discharge | 1 | 2015 | 506 | 0.350 |
Why?
|
| Lymphatic Abnormalities | 3 | 2021 | 36 | 0.350 |
Why?
|
| Informed Consent | 1 | 2014 | 343 | 0.340 |
Why?
|
| Education, Continuing | 1 | 2010 | 30 | 0.330 |
Why?
|
| Career Choice | 2 | 2011 | 162 | 0.320 |
Why?
|
| Chylothorax | 2 | 2021 | 27 | 0.310 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 222 | 0.310 |
Why?
|
| Societies, Medical | 2 | 2011 | 794 | 0.300 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2005 | 69 | 0.270 |
Why?
|
| Cholestasis | 1 | 2008 | 165 | 0.250 |
Why?
|
| Neoplasm Proteins | 3 | 2005 | 677 | 0.240 |
Why?
|
| Hematology | 3 | 2018 | 42 | 0.240 |
Why?
|
| Child | 20 | 2025 | 26299 | 0.230 |
Why?
|
| Costa Rica | 1 | 2025 | 15 | 0.230 |
Why?
|
| Physicians | 2 | 2016 | 634 | 0.230 |
Why?
|
| Algorithms | 2 | 2025 | 1686 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 578 | 0.220 |
Why?
|
| Child, Preschool | 14 | 2025 | 15057 | 0.220 |
Why?
|
| Humans | 44 | 2025 | 131680 | 0.220 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 549 | 0.210 |
Why?
|
| U937 Cells | 2 | 2001 | 23 | 0.200 |
Why?
|
| Sirolimus | 2 | 2021 | 231 | 0.190 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 120 | 0.190 |
Why?
|
| Hemangioma | 1 | 2023 | 92 | 0.190 |
Why?
|
| Antigens, CD | 2 | 2001 | 418 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 1356 | 0.180 |
Why?
|
| Receptors, IgE | 1 | 2001 | 11 | 0.180 |
Why?
|
| Hepatoblastoma | 3 | 2009 | 187 | 0.180 |
Why?
|
| Antigens, CD20 | 1 | 2001 | 44 | 0.170 |
Why?
|
| Angiomatosis | 1 | 2021 | 6 | 0.170 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 34 | 0.170 |
Why?
|
| Infant | 10 | 2025 | 13306 | 0.170 |
Why?
|
| Pleural Effusion | 1 | 2021 | 106 | 0.170 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 3101 | 0.160 |
Why?
|
| Adolescent | 13 | 2025 | 20982 | 0.160 |
Why?
|
| Human Genome Project | 1 | 2000 | 55 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2021 | 120 | 0.160 |
Why?
|
| Genetics, Medical | 1 | 2001 | 119 | 0.160 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2000 | 36 | 0.160 |
Why?
|
| Remission Induction | 3 | 2011 | 309 | 0.160 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2019 | 5 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 295 | 0.160 |
Why?
|
| Thyroid Crisis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Candida tropicalis | 1 | 2019 | 17 | 0.150 |
Why?
|
| Male | 20 | 2025 | 65267 | 0.150 |
Why?
|
| Female | 22 | 2025 | 71186 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2001 | 200 | 0.140 |
Why?
|
| Prednisone | 2 | 2009 | 244 | 0.140 |
Why?
|
| Candidiasis | 1 | 2019 | 132 | 0.140 |
Why?
|
| Peritoneovenous Shunt | 1 | 2018 | 5 | 0.140 |
Why?
|
| Vincristine | 2 | 2009 | 194 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 1617 | 0.140 |
Why?
|
| Genome | 1 | 2000 | 473 | 0.140 |
Why?
|
| Chylous Ascites | 1 | 2017 | 10 | 0.140 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2018 | 28 | 0.130 |
Why?
|
| Gene Expression | 2 | 2014 | 1502 | 0.130 |
Why?
|
| Ascites | 1 | 2018 | 99 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 1387 | 0.130 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 44 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 667 | 0.130 |
Why?
|
| Pediatrics | 3 | 2018 | 1231 | 0.120 |
Why?
|
| Drainage | 1 | 2017 | 253 | 0.120 |
Why?
|
| Prognosis | 5 | 2018 | 4952 | 0.120 |
Why?
|
| Career Mobility | 1 | 2016 | 51 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 904 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 267 | 0.120 |
Why?
|
| Human Rights Abuses | 1 | 2015 | 1 | 0.120 |
Why?
|
| Macrophages | 1 | 2000 | 666 | 0.120 |
Why?
|
| Patient Advocacy | 1 | 2015 | 60 | 0.110 |
Why?
|
| Organizational Policy | 1 | 2015 | 50 | 0.110 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 36 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2009 | 1104 | 0.110 |
Why?
|
| Israel | 1 | 2014 | 48 | 0.110 |
Why?
|
| Anemia | 1 | 2018 | 355 | 0.100 |
Why?
|
| Mental Competency | 1 | 2014 | 55 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2015 | 227 | 0.100 |
Why?
|
| Genomics | 1 | 2001 | 1625 | 0.100 |
Why?
|
| Emergencies | 1 | 2014 | 180 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2002 | 551 | 0.090 |
Why?
|
| Quality of Life | 1 | 2022 | 2118 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 517 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 136 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 590 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2003 | 156 | 0.090 |
Why?
|
| Wnt Proteins | 2 | 2009 | 201 | 0.090 |
Why?
|
| Risk Adjustment | 1 | 2011 | 57 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 100 | 0.080 |
Why?
|
| Global Health | 1 | 2015 | 632 | 0.080 |
Why?
|
| Physicians, Women | 1 | 2011 | 50 | 0.080 |
Why?
|
| Job Satisfaction | 1 | 2010 | 99 | 0.080 |
Why?
|
| RNA, Messenger | 5 | 2003 | 2568 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 172 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1833 | 0.080 |
Why?
|
| Monocytes | 2 | 2002 | 337 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2018 | 366 | 0.080 |
Why?
|
| Daunorubicin | 1 | 2009 | 25 | 0.080 |
Why?
|
| Mechlorethamine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Procarbazine | 1 | 2008 | 11 | 0.070 |
Why?
|
| Asparaginase | 1 | 2009 | 51 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1260 | 0.070 |
Why?
|
| Vinblastine | 1 | 2008 | 55 | 0.070 |
Why?
|
| Minority Groups | 1 | 2011 | 256 | 0.070 |
Why?
|
| Bleomycin | 1 | 2008 | 111 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 2120 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 215 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2009 | 261 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 1322 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 301 | 0.070 |
Why?
|
| Membrane Proteins | 4 | 2009 | 1613 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 961 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2009 | 350 | 0.060 |
Why?
|
| Recurrence | 2 | 2011 | 1483 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12984 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 2037 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2003 | 436 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17667 | 0.060 |
Why?
|
| Syndrome | 1 | 2008 | 1168 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2018 | 3130 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2005 | 65 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 1236 | 0.060 |
Why?
|
| Leukemia | 2 | 2005 | 375 | 0.060 |
Why?
|
| Mice | 2 | 2011 | 18488 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 238 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2001 | 2971 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2002 | 1947 | 0.060 |
Why?
|
| Neoplasms | 2 | 2018 | 2969 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 372 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 191 | 0.050 |
Why?
|
| DNA, Concatenated | 1 | 2003 | 5 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 236 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 786 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6279 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2009 | 984 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2003 | 299 | 0.050 |
Why?
|
| Propranolol | 1 | 2023 | 111 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2011 | 2437 | 0.050 |
Why?
|
| Spectral Karyotyping | 1 | 2002 | 8 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 989 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1277 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 121 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 215 | 0.050 |
Why?
|
| Octreotide | 1 | 2021 | 24 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 69 | 0.040 |
Why?
|
| Acute Disease | 2 | 2002 | 1153 | 0.040 |
Why?
|
| Ligases | 1 | 2001 | 35 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2001 | 25 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2001 | 39 | 0.040 |
Why?
|
| Prevalence | 1 | 2008 | 2694 | 0.040 |
Why?
|
| Embolism, Air | 1 | 2001 | 22 | 0.040 |
Why?
|
| Azathioprine | 1 | 2001 | 37 | 0.040 |
Why?
|
| Endothelium, Lymphatic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Novobiocin | 1 | 1981 | 2 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1981 | 12 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 122 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2001 | 80 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 138 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 10959 | 0.040 |
Why?
|
| Pregnancy | 1 | 2014 | 7572 | 0.040 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2021 | 15 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2001 | 72 | 0.040 |
Why?
|
| Simplexvirus | 1 | 1981 | 100 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2564 | 0.040 |
Why?
|
| Base Sequence | 2 | 2002 | 2783 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2001 | 77 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 529 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 625 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 4050 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 1489 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 53 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2001 | 140 | 0.040 |
Why?
|
| Acetyltransferases | 1 | 2000 | 73 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 3616 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 208 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 432 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 2000 | 236 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2000 | 99 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 2297 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 421 | 0.040 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 130 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 2567 | 0.040 |
Why?
|
| DNA, Viral | 1 | 1981 | 451 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2001 | 198 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 1810 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2001 | 190 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2019 | 101 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 10104 | 0.040 |
Why?
|
| Cunninghamella | 1 | 1998 | 3 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2014 | 670 | 0.040 |
Why?
|
| Botswana | 1 | 2018 | 75 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1397 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 37 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 1610 | 0.040 |
Why?
|
| Mucormycosis | 1 | 1998 | 31 | 0.030 |
Why?
|
| Adult | 5 | 2021 | 31719 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2000 | 314 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2018 | 100 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 1745 | 0.030 |
Why?
|
| Peritoneum | 1 | 2017 | 38 | 0.030 |
Why?
|
| Doxycycline | 1 | 2018 | 115 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 615 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 21261 | 0.030 |
Why?
|
| Bacteremia | 1 | 2001 | 423 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 204 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 148 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8589 | 0.030 |
Why?
|
| Middle Aged | 2 | 2018 | 28889 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 832 | 0.030 |
Why?
|
| DNA | 1 | 1981 | 1442 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1626 | 0.030 |
Why?
|
| HIV-1 | 1 | 2018 | 477 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 490 | 0.030 |
Why?
|
| Genome, Human | 1 | 2001 | 1332 | 0.030 |
Why?
|
| Animals | 4 | 2011 | 34375 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 1122 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 259 | 0.020 |
Why?
|
| Haplotypes | 1 | 2014 | 543 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2014 | 582 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 646 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 773 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 155 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 165 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 126 | 0.020 |
Why?
|
| Cell Division | 2 | 2001 | 731 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 739 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 910 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5297 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2009 | 17 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 1958 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2009 | 38 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2009 | 29 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 1989 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1131 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 6494 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 328 | 0.020 |
Why?
|
| beta Catenin | 1 | 2009 | 209 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 293 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2009 | 296 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 305 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2009 | 204 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 82 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 550 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2007 | 114 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 598 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2143 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 76 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 568 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3917 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2005 | 269 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 703 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2003 | 36 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 127 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2003 | 99 | 0.010 |
Why?
|
| Artificial Gene Fusion | 1 | 2002 | 11 | 0.010 |
Why?
|
| PAX5 Transcription Factor | 1 | 2002 | 16 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 136 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 286 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 609 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 57 | 0.010 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 18 | 0.010 |
Why?
|
| Home Nursing | 1 | 2001 | 13 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 33 | 0.010 |
Why?
|
| Oxolinic Acid | 1 | 1981 | 1 | 0.010 |
Why?
|
| Aminocoumarins | 1 | 1981 | 1 | 0.010 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2001 | 36 | 0.010 |
Why?
|
| Nalidixic Acid | 1 | 1981 | 3 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1799 | 0.010 |
Why?
|
| Coumarins | 1 | 1981 | 23 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2001 | 54 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 755 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 350 | 0.010 |
Why?
|
| Cricetinae | 1 | 1981 | 367 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 1008 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 134 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 577 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3413 | 0.010 |
Why?
|
| Pyrroles | 1 | 1981 | 186 | 0.010 |
Why?
|
| Radiography | 1 | 2001 | 762 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 680 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2001 | 364 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 777 | 0.010 |
Why?
|
| Virus Replication | 1 | 1981 | 597 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 636 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1998 | 151 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1788 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 313 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3454 | 0.010 |
Why?
|
| Cell Line | 1 | 1981 | 2605 | 0.010 |
Why?
|
| Survivors | 1 | 1998 | 354 | 0.010 |
Why?
|
| United States | 1 | 2011 | 11804 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 1170 | 0.010 |
Why?
|
| Genotype | 1 | 2001 | 2655 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 1939 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 4516 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 6177 | 0.000 |
Why?
|